nuttapong/iStock Editorial via Getty Images Introduction Last year, I started covering Johnson & Johnson (JNJ), one of the biggest healthcare companies in the world. However, the company, which sports a triple-A credit rating, got into trouble due to a number of lawsuits and weak growth. This turned it into an underperforming asset and forced it to make some radical decisions, including the spin-off of its consumer segment, which it had been streamlining since 2019. The spin-off has been a public company fo ...